Clinical trials: Functional Neurological Disorders
- Condition Functional Neurological Disorders
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Sensorimotor Gait Disorder, Neurologic Ambulation Disorder
Clinical Study of the L300 Versus Ankle-foot Orthosis (AFO) on Post-Stroke Subjects With Foot Drop
The objective of this study is to determine the effectiveness of the NESS L300 (L300) in improving gait parameters, function, and quality of life among stroke subjects (greater than or equal to 3 months post stroke)with drop foot.
- Conditions
- Sensorimotor Gait Disorder, Neurologic Ambulation Disorder, Gait, Drop Foot, Poststroke Hemiparesis
- Trial name
- L300 (NCT01138995)
- Testing
- Ness L300, Ankle-foot orthosis
- Where
- 11 sites in United States
- Volunteers
- 197 people
- Sponsor
- Bioness Inc
Irritable Bowel Syndrome
Olorinab in Irritable Bowel Syndrome With Predominant Constipation (IBS-C) and Irritable Bowel Syndrome With Predominant Diarrhea (IBS-D)
The purpose of this study is to determine whether olorinab is a safe and effective treatment for abdominal pain in participants with irritable bowel syndrome (IBS).
- Trial name
- CAPTIVATE (NCT04043455)
- Testing
- Olorinab
- Where
- 69 sites in United States
- Volunteers
- 273 people
- Sponsor
- Arena Pharmaceuticals
Huntington's Disease
Randomized, Placebo Controlled Study Of The Efficacy And Safety Of PF-02545920 In Subjects With Huntington's Disease
This study is a 26 week, randomized, parallel group, double blind comparison of PF-02545920 5 mg, PF-02545920 20 mg, and placebo dosed BID in the treatment of motor impairment of subjects with Huntington's Disease.
- Trial name
- NCT02197130
- Testing
- PF-02545920
- Where
- 57 sites in United States, Canada and 3 more
- Volunteers
- 272 people
- Sponsor
- Pfizer
Muscular Dystrophy, Duchenne, Ambulatory Care
Phase III Study of Idebenone in Duchenne Muscular Dystrophy (DMD)
The aim of this Phase III study was to assess the efficacy of idebenone on pulmonary function, motor function, muscle strength and quality of life in patients with DMD.
- Trial name
- DELOS (NCT01027884)
- Testing
- Idebenone
- Where
- 23 sites in United States, Austria and 8 more
- Volunteers
- 65 people
- Sponsor
- Santhera Pharmaceuticals
Nonhemorrhagic Ischemic Stroke, Motor Function
Observational Study to Evaluate the Simplified-STroke REhabilitation Assessment of Movement (S-STREAM) Scale in Subjects Who Have Experienced a Nonhemorrhagic Ischemic Stroke
The purpose of this study is to evaluate the utility of the S-STREAM as an instrument to assess motor function in subjects who have experienced a nonhemorrhagic ischemic stroke.
- Trial name
- NCT01496885
- Testing
- Observational study
- Where
- 27 sites in United States, Canada
- Volunteers
- 120 people
- Sponsor
- Daiichi Sankyo
Cerebral Palsy (CP)
Safety and Tolerability of Dalfampridine in Subjects With Cerebral Palsy
A double-blind, placebo-controlled, crossover study in subjects with cerebral palsy (CP) to evaluate the safety and tolerability and the effect of dalfampridine extended release (ER) tablets on sensorimotor function
- Trial name
- NCT01468350
- Testing
- dalfampridine-ER 10mg
- Where
- 11 sites in United States
- Volunteers
- 35 people
- Sponsor
- Acorda Therapeutics
Cerebrovascular Stroke, Upper Extremity Paresis
Pivotal Study of VNS During Rehab After Stroke (VNS-REHAB)
This is a pivotal phase study of up to 120 subjects and 15 clinical sites. All subjects are implanted with the Vivistim System® and then randomized to either study treatment or active-control treatment.
- Trial name
- VNS-REHAB (NCT03131960)
- Testing
- Paired Vagus Nerve Stimulation, Rehabilitation
- Where
- 20 sites in United States, United Kingdom
- Volunteers
- 108 people
- Sponsor
- MicroTransponder Inc.
Fabry Disease
Study of the Safety and Efficacy of PRX-102 Compared to Agalsidase Beta on Renal Function
This was a randomized, double-blind, active control study of the enzyme replacement therapy (ERT) drug PRX-102 (pegunigalsidase alfa) in Fabry disease patients with impaired renal function.
- Trial name
- BALANCE (NCT02795676)
- Testing
- PRX-102 (pegunigalsidase alfa), agalsidase beta
- Where
- 29 sites in United States, Czechia and 10 more
- Volunteers
- 78 people
- Sponsor
- Protalix
Parkinson's Disease
Randomized Evaluation of the 24-Hour Coverage: Efficacy of Rotigotine
The objective of this trial is to assess the effects of transdermal rotigotine on the control of early morning motor function and sleep disorders compared to placebo in subjects with idiopathic Parkinsons´s disease.
- Trial name
- RECOVER (NCT00474058)
- Testing
- Rotigotine
- Where
- 47 sites in United States, Australia and 10 more
- Volunteers
- 287 people
- Sponsor
- UCB Pharma
Obstructive Sleep Apnea
FAST as a Treatment for Obstructive Sleep Apnea
The objective of this study is to assess the feasibility and safety of tongue suspension using the Siesta Medical Encore Tongue Suspension System for the treatment of obstructive sleep apnea (OSA).
- Trial name
- FAST (NCT01611779)
- Testing
- Encore Tongue Suspension System
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Siesta Medical, Inc.
Brain Injuries, Growth Hormone Deficiency
Treatment Of Adult Growth Hormone Deficiency After Traumatic Brain Injury
To establish the effects of genotropin replacement on cognitive function in patients with severe growth hormone deficiency after traumatic brain injury.
- Trial name
- NCT00555009
- Testing
- Genotropin
- Where
- 9 sites in France, Italy and 4 more
- Volunteers
- 10 people
- Sponsor
- Pfizer
Alzheimer's Disease
Computerized Cognition Testing in Participants With Mild Alzheimer's Disease (AD) Treated With Donepezil (MK-0000-318)
This study aims to determine whether the Cogstate testing battery can detect improvements in cognitive function in participants with mild AD.
- Trial name
- NCT02064920
- Testing
- Donepezil
- Volunteers
- 36 people
- Sponsor
- Merck Sharp & Dohme LLC
Joint Diseases, Arthritis
A Study to Compare the Frequency of Constipation Symptoms With Tapentadol Immediate Release (IR) Treatment Versus Oxycodone IR Treatment in Patients With End-stage Joint Disease
The purpose of this study is to compare bowel function/constipation that occurs during tapentadol treatment with that occuring during oxycodone treatment, as measured by the frequency of spontaneous bowel movements per week.
- Conditions
- Joint Diseases, Arthritis, Osteoarthritis
- Trial name
- NCT00784277
- Testing
- oxycodone CR, oxycodone IR, Tapentadol ER (CG5503)
- Volunteers
- 597 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Parkinson's Disease
Long-term Extension of RECOVER- Long-term Effect of the 24h Transdermal Delivery of Rotigotine in Subjects With Idiopathic Parkinson's Disease
The objective of this open-label extension is to assess the long-term effect of the 24-hour transdermal delivery of rotigotine on motor function, sleep quality, and nocturnal and non-motor symptoms of Parkinson's disease.
- Trial name
- NCT00519532
- Testing
- Rotigotine
- Where
- 21 sites in United States, Australia and 9 more
- Volunteers
- 84 people
- Sponsor
- UCB Pharma
Alzheimer's Disease, Sleep Disorder
Efficacy of Circadin® 2 mg in Patients With Mild to Moderate Alzheimer Disease Treated With AChE Inhibitor
The aim of this exploratory randomized, placebo controlled study is to evaluate the efficacy of Circadin® 2mg in patients with mild to moderate Alzheimer Disease (AD) treated with the acetylcholinesterase (AChE) inhibitor.
- Trial name
- NCT00940589
- Testing
- Circadin
- Where
- 6 sites in United States, Israel and 1 more
- Volunteers
- 73 people
- Sponsor
- Neurim Pharmaceuticals Ltd.
Muscular Atrophy, Spinal
Safety and Efficacy of Intravenous OAV101 (AVXS-101) in Pediatric Patients With Spinal Muscular Atrophy (SMA) (OFELIA)
This was a phase IV Open-label, single-arm, single-dose, multicenter study, to evaluate the safety, tolerability and efficacy of intravenous administration of OAV101 (AVXS-101) in patients with SMA with bi-allelic mutations in…
- Trial name
- OFELIA (NCT05073133)
- Testing
- OAV101
- Where
- 5 sites in Argentina, Brazil
- Volunteers
- 16 people
- Sponsor
- Novartis Pharmaceuticals
Alzheimer's Disease
A Study of Gantenerumab in Participants With Prodromal Alzheimer's Disease
This multi-center, randomized, double-blind, placebo-controlled parallel-group study will evaluate the effect of gantenerumab (RO4909832) on cognition and functioning and the safety and pharmacokinetics in participants with…
- Trial name
- Scarlet Road (NCT01224106)
- Testing
- Gantenerumab
- Where
- 139 sites in United States, Argentina and 22 more
- Volunteers
- 799 people
- Sponsor
- Hoffmann-La Roche
Epilepsy
Effects of Eslicarbazepine Acetate (BIA 2-093) on Cognition and Psychomotor Function
Single-blind, single-centre, fixed-order study to evaluate the PD effects of a single oral dose and multiple oral doses of ESL (BIA 2-093) in healthy volunteers.
- Trial name
- NCT02284828
- Testing
- BIA 2-093
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Insomnia
Pharmacokinetics of Suvorexant in Participants With Impaired Renal Function (MK-4305-023)(COMPLETED)
This study will investigate whether the plasma concentration-time profile and pharmacokinetics (PK) of suvorexant (MK-4305) in participants with impaired renal function are similar to those observed in healthy participants; and…
- Trial name
- NCT01059851
- Testing
- Suvorexant
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Irritable Bowel Syndrome
Study to Evaluate the Efficacy and Safety of Vibegron Administered Orally for 12 Weeks to Women With Irritable Bowel Syndrome
This study will evaluate the efficacy and safety of vibegron, a beta-3 adrenergic receptor (β3-AR) agonist, in the treatment of pain associated with irritable bowel syndrome (IBS) due to IBS with predominant diarrhea (IBS-D) or…
- Trial name
- NCT03806127
- Testing
- Vibegron
- Where
- 41 sites in United States
- Volunteers
- 222 people
- Sponsor
- Urovant Sciences GmbH